Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: Conbercept in nAMD
NCT01436864Phase 3Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Aug 2011
- Primary completion
- Dec 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in neovascular age-related macular degeneration (NVAMD), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Aug 2011; status: completed.
02
Drugs
conbercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01436864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436864.